Product Description: Exendin-4 (Exenatide), a 39 amino acid peptide, is a long-acting glucagon-like peptide-1 receptor agonist with an IC50 of 3.22 nM.
Applications: Metabolism-sugar/lipid metabolism
Formula: C184H282N50O60S
Citations: Acta Biochim Biophys Sin (Shanghai). 2017 Jul 1;49(7):573-580./Am J Physiol Cell Physiol. 2024 May 13./Am J Physiol Endocrinol Metab. 2020 Dec 1;319(6):E1019-E1030./Annals of the Romanian Society for Cell Biology. 2021 Mar 15./Asian J Pharm Sci. 2024 Mar 12, 100904./Biochim Biophys Acta Mol Cell Res. 2022 May 27;1869(9):119300./Biomacromolecules. 2024 Jul 1./Biomedicines. 2020 Nov 9;8(11):485./bioRxiv. 2020 Jul./bioRxiv. 2024 August 10./bioRxiv. 2024 Mar 20./bioRxiv. 2024 May 3./bioRxiv. 2024 May 8./BMC Biol. 2021 Mar 3;19(1):40./Br J Pharmacol. 2020 Aug;177(15):3389-3402. /Br J Pharmacol. 2024 May 28./Br J Pharmacol. 2024 Sep 26./Chem Biol Interact. 2019 May 1;304:186-193./Drug Deliv. 2022 Dec;29(1):548-560./Eur J Pharmacol. 2024 Nov 6:985:177106./Eur J Pharmacol. 2024 Oct 2:177029./Exp Cell Res. 2023 Jan 7;113469./Front Behav Neurosci. 05 January 2022./Front Pharmacol. 2019 Oct 25;10:1230./Front Pharmacol. 2021 Jul 19;12:694476./Gerontology. 2023 Mar 7;1-12./Gut. 2022 Jun 13;gutjnl-2021-326541./Inflamm Res. 2024 May 15./Insects. 2024 Jul 5./Int Immunopharmacol. 2021 Jan;90:107192./Int Immunopharmacol. 2023 May 19;120:110339./Int Immunopharmacol. 2024 Aug 1:140:112844./Int J Biol Sci. 2022; 18(4): 1328-1346./Int J Nanomedicine. 2025 Mar 17:20:3363-3378./J Adv Res. 2025 Mar 10:S2090-1232(25)00174-2./J Biol Chem. 2018 Nov 23;293(47):18086-18098. /J Cell Physiol. 2021 May;236(5):3641-3659./J Diabetes Res. 2019 Dec 9;2019:8905917./J Funct Foods. 2023 Aug, 107, 105706./J Invest Dermatol. 2021 Oct 20;S0022-202X(21)02369-1./J Neuroinflammation. 2019 Nov 28;16(1):242./medRxiv. 2024 Jul 23./Mol Med. 2024 May 8;30(1):58./Mol Metab. 2023 Sep 26, 101811./Nature. 2025 Mar 5./Neural Regen Res. 2022./Neurogastroenterol Motil. 2019 Feb;31(2):e13482./Res Sq. 2024 Aug 11./Sci Rep. 2017 Jun 28;7(1):4351./Sci Rep. 2024 Jun 14;14(1):13726./SSRN. 2019 Jun 27./Structure. 2022 Feb 2;S0969-2126(22)00006-5./Biomaterials. 2021 Aug;275:120944.
References: [1]Doyle ME, et al. The importance of the nine-amino acid C-terminal sequence of exendin-4 for binding to the GLP-1 receptor and for biological activity. Regul Pept. 2003 Jul 15;114(2-3):153-8./[2]Wei R, et al. Exenatide exerts direct protective effects on endothelial cells through the AMPK/Akt/eNOS pathway in a GLP-1 receptor-dependent manner. Am J Physiol Endocrinol Metab. 2016 Jun 1;310(11):E947-57./[3]Fidan-YaylalI G, et al. Antidiabetic exendin-4 activates apoptotic pathway and inhibits growth of breast cancer cells. Tumour Biol. 2016 Feb;37(2):2647-53./[4]Ding X, et al. Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/obmice. Hepatology. 2006 Jan;43(1):173-81./[5]Nachnani JS, et al. Biochemical and histological effects of exendin-4 (exenatide) on the rat pancreas. Diabetologia. 2010 Jan;53(1):153-9./[6]Selley E, et al. Exenatide induces aortic vasodilation increasing hydrogen sulphide, carbon monoxide and nitric oxide production. Cardiovasc Diabetol. 2014 Apr 2;13:69.
CAS Number: 141758-74-9
Molecular Weight: 4186.57
Compound Purity: 99.95
Research Area: Metabolic Disease; Cardiovascular Disease; Cancer
Solubility: DMSO : ≥ 32 mg/mL/Ethanol : < 1 mg/mL (ultrasonic;warming;heat to 60°C)/H2O : 33.33 mg/mL (ultrasonic)
Target: GCGR
English
Deutsch
